title: [Intravitreal bevacizumab injections versus verteporferin photodynamic therapy for macular choroidal neovascularization in high myopia: 24-month follow-up].
abstract: OBJECTIVE
  To compare the long-term safety and of intravitreal bevacizumab injections (IVB) and verteporferin photodynamic therapy (PDT) in the treatment of choroidal neovascularization (CNV) in high myopia.
  
  
  METHODS
  Review of retrospectively collected data of 60 eyes of 60 patients with high myopic choroidal neovascularization treated either with standard PDT (PDT group; n=30) or IVB injections (IVB group; n=30). The two groups were compared at baseline, 3, 6,12 and 24 months.
  
  
  RESULTS
  In the IVB group, mean best corrected visual acuity (BCVA) was significantly improved at 3 to 12 months; however, the significance was lost at 24 months. The PDT group showed an insignificant improvement at 3 and 6 months, then worsened at 12 and 24 months. Mean BCVA was better in the IVB group than the PDT group at 3, 6, 12 and 24 months. The decrease in mean central macular thickness was significantly higher in the IVB group than in the PDT group at 3, 6, 12 and 24 months. At 24 months, chorioretinal atrophy was noted in five eyes (16.6%) treated with IVB and in 22 eyes (73.3%) treated with PDT (P=2×10(-5)).
  
  
  CONCLUSIONS
  IVB provides significantly better BCVA than PDT for high myopic CNV over the long-term.
authors.affiliation: Service d'ophtalmologie B, institut Hédi Rais d'ophtalmologie, boulevard 9-Avril, 1006 Tunis, Tunisie. leila.elmatri@rns.tn
authors.forename: L
authors.initials: L
authors.lastname: El Matri
authors.forename: A
authors.initials: A
authors.lastname: Chebil
authors.forename: R
authors.initials: R
authors.lastname: Bouraoui
authors.forename: F
authors.initials: F
authors.lastname: Kort
authors.forename: M
authors.initials: M
authors.lastname: Bouladi
authors.forename: S
authors.initials: S
authors.lastname: Basaraih
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000188:drug therapy* / Q000209:etiology; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage*; D011166:Porphyrins / Q000008:administration & dosage*; D012189:Retrospective Studies; D000077362:Verteporfin; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D000068258:Bevacizumab